An overview of the preclinical toxicity and potential carcinogenicity of sitaxentan (Thelin®), a potent endothelin receptor antagonist developed for pulmonary arterial hypertension
- Resource Type
- Article
- Source
- In
Regulatory Toxicology and Pharmacology October 2012 64(1):95-103 - Subject
- Language
- ISSN
- 0273-2300